AIHealthcare Analytics

Knowledge Wiki

Wiki › FDA Regulatory Framework for AI Medical Devices — TEMPO Pilot and Generative AI Pathways

FDA Regulatory Framework for AI Medical Devices — TEMPO Pilot and Generative AI Pathways

OVERVIEW
Rev 4 Oct 7, 2026 11:33 UTC 3 sources

The FDA has outlined a 2026-2027 regulatory roadmap emphasizing the TEMPO (Total, Efficient, Modern, Pre-approval and Ongoing) pilot pathway for generative AI medical devices. TEMPO provides a pre-authorization pathway enabling companies to deploy generative AI tools in clinical settings while gathering real-world evidence before formal FDA authorization. The TEMPO approach reflects FDA recognition that traditional pre-market clinical trial data may be insufficient for generative AI systems that adapt and evolve post-deployment. The pathway enables iterative improvement while maintaining safety oversight through real-world evidence collection and performance monitoring requirements. However, the TEMPO pathway raises questions about appropriate regulatory rigor. Critics argue that allowing deployment before authorization creates risks of widespread harm before safety issues are detected. Supporters contend that traditional pre-market pathways are too slow for rapidly evolving AI technologies. The FDA's 2026-2027 guidance development will clarify expectations for real-world evidence collection, performance monitoring, and safety thresholds for TEMPO authorized devices. ---

Sources: harvested
🔒

Subscribe to read full wiki analysis

Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.

View Plans & Subscribe

New users get a 7-day trial — no credit card required.

← Back to Wiki Index